Findings With the Antibody Drug Conjugate D3-GPC2-PBD

Kristopher Bosse, MD

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses findings with the antibody-drug conjugate (ADC) D3-GPC2-PBD for neuroblastoma presented at the 2018 AACR Annual Meeting.

The novel ADC D3-GPC2-PBD was developed for neuroblastoma linking to a specific glypican 2 targeting antibody to the DNA damaging pyrrolobenzodiazepine dimers. This ADC was used in panel of neuroblastoma patient-derived xenografts.